Singapore, Feb. 25 -- How would you characterise Europe's biotech position today compared with the US and Asia as we move into 2026?

As of 2026, Europe maintains a strong scientific foundation but faces a critical "processing gap". While the United States remains the global leader in raw AI investment and the Asia-Pacific region has become a "capability powerhouse" in AI adoption, Europe is struggling with the transition from pen-and-paper to a fully digitised ecosystem.

We view the current landscape through these lenses:

What structural strengths give Europe a credible edge as a global biotech innovation hub?

Europe's edge lies in its deep scientific roots and the potential for a "connected" model of intelligence. I argue that Europe...